Biotech Values

[wallstarb]

ASCO pretty much a bust this year for small cap biotechs. Some interesting studiez anddata from some of the big pharma/biopharma, but nothing really earth shattering for smaller cap stocks which would really have significant %moves based on data.

Going forward with ASCO out of the way there will be a HUGE slowdown in newsflow for biotech in general and with that I would expect interest to wane as mauch of the "fast money" sells or has sold and the demand from those sorts of investors/traders leave the sector post ASCO.

I am keeping our short bias for the next few months but will be on the looout for any screaming bargains not many I see right now, but I am noticing some starting to seem more interesting.

Hopefully a number of these stocks can take advantage of their high prices to raise some cash.